FIRE Funds Income Target ETF FIRI 深 滬
等待開盤 11-04 09:30:00 美东时间
18.9449
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 18.9449
- 總市值 123.14万
- 52周最高 19.115
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 17.6612
- 委 比 0.00%
- 總股本 6.50万
- 歷史最高 18.1637
- 量 比 0
- 振 幅 0.00%
- 歷史最低 17.7417
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
Oncolytics Biotech Inc. reported updated data from Cohort 4 of its Phase 1/2 GOBLET study, showing pelareorep combined with atezolizumab achieved a median duration of response of approximately 15 months in second-line squamous cell anal cancer patients, exceeding historical results of 9.5 months for approved monotherapy. All responding patients survived over one year, with some exceeding 24 months. The FDA's Fast Track Designation and regulatory ...
10-27 13:30
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
<p>At the 2026 ESMO Congress, BioNTech will present new clinical data from its late-stage oncology pipeline, including updates on pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, in combination with docetaxel for second-line metastatic non-small cell lung cancer (NSCLC). Additionally, data on pumitamig combined with elfetabart drozuntecan, a B7-H3-targeting antibody-drug conjugate, will be showcased across multiple advanced solid tumors. The...
10-19 10:45
AIM ImmunoTech Reports Positive Phase 2 DURIPANC Update As Final Patient Enrolled In Pancreatic Cancer Trial
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with
06-08 20:36
Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone- Patients with P53WT genomics
06-01 19:07
Cardiff Oncology Reveals Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib In First-Line RAS-Mutated mCRC
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it will host an investor webcast featuring members of
05-22 05:06
Oncolytics Biotech Announces Its Data From REO 022 Trial In Metastatic Colorectal Cancer Shows 19.5-Month Median Duration Of Response In Second-Line KRAS-Mutant MSS mCRC Participants
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate
05-04 21:02
